Immune Responses to Arexvy in Adults aged 50 to 59 Years Noninferior to those in Adults aged 60 Years and Older
The comparable immune responses were observed in 50-to 59-year-olds at high risk of RSV-LRTD as well as a wider group at average risk, according to preliminary phase 3 data.
Pediatric Disability and Poverty: A Symbiotic System
Poverty is both a cause and a consequence of disability, says pediatric rehabilitation physician Dr Amy Houtrow. She explains more about the connections in this short video.
Migraine in Pregnancy & Lactation: Considerations for Treatment
Get details on which migraine treatments are the better option for women who are breastfeeding, and on ones to advise them to avoid.
Daily Dose: Novel Intranasal COVID-19 Vaccine Induces Strong Immune Response
Your daily dose of the clinical news you may have missed.
Migraine in Pregnancy: Considerations for Treatment
An overview of safe treatment options for migraine attacks that may occur during pregnancy for primary care clinicians, here.
CDC Health Advisory: Nirsevimab Shortage to Last All RSV Season
The 100 mg dose prefilled syringes are in particularly short supply and while the shortage of the 50 mg dose is not as severe, supply will be limited this season.
Clinical Implementation of Cancer Screening Strategies
Experts delve into the complexities of cancer screening, from identifying high-risk individuals to counseling patients about the nuances of screening tests, all while aiming for early detection and improved outcomes.
Navigating the Transition to Precision Medicine in Early Cancer Detection
Experts discuss the transition from evidence-based medicine to precision medicine in the context of cancer screening, emphasizing the urgency of implementing multi-cancer screening for broad positive outcomes.
IDWeek 2023: 8 Research Briefs for Primary Care
Get a topline look at 8 of the many studies premiered at IDWeek that have outcomes of interest to primary care clinicians.
Axsome's AXS-05 Significantly Reduced Risk of Relapse in Alzheimer Agitation in Phase 3 ACCORD Trial
Findings from phase 3 ACCORD clinical trial demonstrated rapid and sustained clinical response in patients with Alzheimer disease agitation with no new safety signals reported.
Tirzepatide Ups Mean Weight Loss by 21% Following Intensive Lifestyle Intervention: SURMOUNT-3
Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.
Daily Dose: Obesity Linked to Higher Risk for Breast Cancer Recurrence
GALACTIC Trial: RAAS Inhibitor Uptitration Less Successful in Women
Uptitration of renin-angiotensin-aldosterone system inhibitors was less successful in women with acute heart failure, and particularly those with heart failure with reduced ejection fraction.
Daily Dose: Real-World Use of Cabotegravir for HIV PrEP
Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair
Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.
FDA Accepts sBLA for Self-Administered Intranasal Influenza Vaccine from AstraZeneca
The flexibility to self administer a flu vaccine or to administer to another in a non-clinical setting could greatly expand both access and vaccine uptake.
Identifying and Managing CKD With Other Comorbid Conditions
Experts highlight considerations for patients with chronic kidney disease and other comorbid conditions, particularly diabetes, in terms of screening and preventative care.
Filling the Gap: Testing to Identify Early-Stage CKD
Experts discuss key challenges in testing and diagnosing a patient with chronic kidney disease, especially for those who are asymptomatic. In addition, they highlight new screening approaches to accurately identify these patients.
Combination Influenza/COVID-19 Vaccine Enters Phase 3 Trial, First Participant Dosed
The investigational combination vaccine against influenza and SARS-CoV-2 proved both safe and effective in recent results from a phase 1/2 trial, said Moderna.
Daily Dose: Obesity Before and During Pregnancy Predicts Future CV Health